申请人:MERCK SHARP & DOHME
公开号:WO2014099836A1
公开(公告)日:2014-06-26
Compounds having the structure of Formula (I), including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and may be useful for raising HDL-cholesterol and reducing LDL-cholesterol in human patients and for treating or preventing atherosclerosis. The chemical compounds that are disclosed cholesterol ester transfer protein (CETP) and are expected to have utility in raising HDL-C, lowering LDL-C, and in the treatment and prevention of atherosclerosis.
具有Formula (I)结构的化合物,包括这些化合物的药用盐,是CETP抑制剂,可能对提高人体患者的HDL胆固醇和降低LDL胆固醇,以及治疗或预防动脉粥样硬化有用。这些化学化合物揭示了胆固醇酯转移蛋白(CETP),预计在提高HDL-C、降低LDL-C以及治疗和预防动脉粥样硬化方面具有用途。